Atjaunināt sīkdatņu piekrišanu

E-grāmata: British Pharmacopoeia, 1864 to 2014: Medicines, International Standards and the State

Citas grāmatas par šo tēmu:
  • Formāts - PDF+DRM
  • Cena: 50,08 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
Citas grāmatas par šo tēmu:

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

The British Pharmacopoeia has provided official standards for the quality of substances, medicinal products and articles used in medicine since its first publication in 1864. It is used in over 100 countries and remains an essential global reference in pharmaceutical research and development and quality control. This book explores how these standards have been achieved through a comprehensive review of the history and development of the pharmacopoeias in the UK, from the early London, Edinburgh and Dublin national pharmacopoeias to the creation of the British Pharmacopoeia and its evolution over 150 years. Trade in medicinal substances and products has always been global, and the British Pharmacopoeia is placed in its global context as an instrument of the British Empire as it first sought to cover the needs of countries such as India and latterly as part of its role in international harmonisation of standards in Europe and elsewhere. The changing contents of the pharmacopoeias over this period reflect the changes in medical practice and the development of dosage forms from products dispensed by pharmacists to commercially manufactured products, from tinctures to the latest monoclonal antibody products. The book will be of equal value to historians of medicine and pharmacy as to practitioners of medicine, pharmacy and pharmaceutical analytical chemistry.

Recenzijas

"In this book Cartwright illustrates the shifting nature of the BPs purpose, its contents, and its intended audience, over the 150 years from 1864 to 2014... the book has much to offer historians of medicine." - Stuart Anderson, London School of Hygiene and Tropical Medicine,Bulletin of the History of Medicine

List of Figures
vii
About the Author ix
Preface xi
Acknowledgements xiii
List of Acronyms and Abbreviations
xv
Notes on References xix
Disclaimer xxi
PART I ORIGINS, DEVELOPMENT AND MATURITY
1 The Earlier British National Pharmacopoeias: London, Edinburgh and Dublin
3(26)
2 Early Years: 1864--1914
29(18)
3 Middle Years: 1914--1968
47(46)
4 Later Years: 1968--2014
93(46)
PART II THE BRITISH PHARMACOPOEIA IN INTERNATIONAL CONTEXT
5 British Pharmacopoeia and the European Pharmacopoeia
139(12)
6 International Harmonisation of Pharmacopoeias
151(14)
PART III CHANGE AND CONTINUITY
7 Changes in Therapeutics 1864--2014
165(40)
8 Changes in Analytical Methods 1864--2014
205(28)
Index 233
Anthony C. Cartwright is a retired Pharmaceutical Regulatory Consultant with over 40 years involvement with national and international regulatory standards for pharmaceuticals, and over 30 years involvement with the British Pharmacopoeia, firstly as an employee and then as a member of its advisory committees. He has written many reviews and research articles, written and co-edited three text books on pharmaceutical regulation and contributed chapters to four others.